title: A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
abstract: OBJECTIVE
  Endothelial dysfunction is an early manifestation of vascular injury and contributes to the development of atherosclerotic cardiovascular disease. Recent studies have implicated hyperuricemia as a risk factor for cardiovascular disease. We hypothesized that lowering uric acid in subjects with asymptomatic hyperuricemia with allopurinol might improve endothelial dysfunction, BP, estimated GFR (eGFR), and inflammatory markers.
  
  
  METHODS
  Subjects with asymptomatic hyperuricemia and no history of gout and 30 normouricemic control subjects were enrolled in this 4-month randomized prospective study. Thirty hyperuricemic patients received 300 mg/d allopurinol and were compared with 37 hyperuricemic patients and 30 normouricemic subjects in matched control groups. Flow-mediated dilation (FMD), eGFR, ambulatory BP monitoring, spot urine protein-creatine ratio, and highly sensitive C-reactive protein were measured at baseline and at 4 months.
  
  
  RESULTS
  Age, gender, lipid profile, eGFR, hemoglobin, glucose, and level of proteinuria were similar in hyperuricemic subjects and controls at baseline. As expected, hyperuricemic patients had higher levels of highly sensitive C-reactive protein and lower FMD compared with normouricemic patients. Allopurinol treatment resulted in a decrease in serum uric acid, a decrease in systolic BP, an increase in FMD, and an increase in eGFR compared with baseline. No significant difference was observed in the control hyperuricemic and normouricemic groups. In a multiple regression analysis, FMD levels were independently related to uric acid both before (beta = -0.55) and after (beta = -0.40) treatment.
  
  
  CONCLUSIONS
  Treatment of hyperuricemia with allopurinol improves endothelial dysfunction and eGFR in subjects with asymptomatic hyperuricemia.
authors.affiliation: Alparslan Mahallesi, Umit sokak, No. 25/14, Melikgazi, Kayseri, Turkey. drkanbay@yahoo.com
authors.forename: Mehmet
authors.initials: M
authors.lastname: Kanbay
authors.forename: Bulent
authors.initials: B
authors.lastname: Huddam
authors.forename: Alper
authors.initials: A
authors.lastname: Azak
authors.forename: Yalcin
authors.initials: Y
authors.lastname: Solak
authors.forename: Gulay Kocak
authors.initials: GK
authors.lastname: Kadioglu
authors.forename: Ismail
authors.initials: I
authors.lastname: Kirbas
authors.forename: Murat
authors.initials: M
authors.lastname: Duranay
authors.forename: Adrian
authors.initials: A
authors.lastname: Covic
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Johnson
mesh_terms: D000328:Adult; D000493:Allopurinol / Q000627:therapeutic use*; D000704:Analysis of Variance; D058070:Asymptomatic Diseases; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D002097:C-Reactive Protein / Q000378:metabolism; D003404:Creatinine / Q000652:urine; D004730:Endothelium, Vascular / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D033461:Hyperuricemia / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D018836:Inflammation Mediators / Q000097:blood; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011507:Proteinuria / Q000209:etiology; D012044:Regression Analysis; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey; D014463:Ultrasonography; D014527:Uric Acid / Q000097:blood; D014664:Vasodilation / Q000187:drug effects
chemical_list: D015415:Biomarkers; D018836:Inflammation Mediators; D014527:Uric Acid; D000493:Allopurinol; D002097:C-Reactive Protein; D003404:Creatinine